As of 2025-05-16, the EV/EBITDA ratio of Cyclo Therapeutics Inc (CYTH) is -1.38. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CYTH's latest enterprise value is 34.97 mil USD. CYTH's TTM EBITDA according to its financial statements is -25.37 mil USD. Dividing these 2 quantities gives us the above CYTH EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.9x - 13.3x | 13.1x |
| Forward P/E multiples | 16.5x - 30.7x | 19.0x |
| Fair Price | (13.04) - (10.56) | (12.71) |
| Upside | -1909.8% - -1565.4% | -1863.8% |
| Date | EV/EBITDA |
| 2025-03-25 | -1.38 |
| 2025-03-24 | -1.37 |
| 2025-03-21 | -1.35 |
| 2025-03-20 | -1.33 |
| 2025-03-19 | -1.31 |
| 2025-03-18 | -1.29 |
| 2025-03-17 | -1.30 |
| 2025-03-14 | -1.35 |
| 2025-03-13 | -1.35 |
| 2025-03-12 | -1.32 |
| 2025-03-11 | -1.32 |
| 2025-03-10 | -1.35 |
| 2025-03-07 | -1.40 |
| 2025-03-06 | -1.42 |
| 2025-03-05 | -1.37 |
| 2025-03-04 | -1.37 |
| 2025-03-03 | -1.42 |
| 2025-02-28 | -1.43 |
| 2025-02-27 | -1.44 |
| 2025-02-26 | -1.44 |
| 2025-02-25 | -1.43 |
| 2025-02-24 | -1.48 |
| 2025-02-21 | -1.62 |
| 2025-02-20 | -1.67 |
| 2025-02-19 | -1.68 |
| 2025-02-18 | -1.65 |
| 2025-02-14 | -1.71 |
| 2025-02-13 | -1.79 |
| 2025-02-12 | -1.65 |
| 2025-02-11 | -1.64 |
| 2025-02-10 | -1.65 |
| 2025-02-07 | -1.99 |
| 2025-02-06 | -1.44 |
| 2025-02-05 | -1.48 |
| 2025-02-04 | -1.48 |
| 2025-02-03 | -1.43 |
| 2025-01-31 | -1.44 |
| 2025-01-30 | -1.36 |
| 2025-01-29 | -1.45 |
| 2025-01-28 | -1.47 |
| 2025-01-27 | -1.48 |
| 2025-01-24 | -1.51 |
| 2025-01-23 | -1.49 |
| 2025-01-22 | -1.49 |
| 2025-01-21 | -1.53 |
| 2025-01-17 | -1.48 |
| 2025-01-16 | -1.46 |
| 2025-01-15 | -1.42 |
| 2025-01-14 | -1.33 |
| 2025-01-13 | -1.30 |